Asset Details
Do you wish to reserve the book?
Arrhythmias and Cardiogenic Shock: A Rare Disease Presentation of Diffuse Large B-Cell Lymphoma with Cardiac Involvement
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Arrhythmias and Cardiogenic Shock: A Rare Disease Presentation of Diffuse Large B-Cell Lymphoma with Cardiac Involvement
Do you wish to request the book?
Arrhythmias and Cardiogenic Shock: A Rare Disease Presentation of Diffuse Large B-Cell Lymphoma with Cardiac Involvement
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Arrhythmias and Cardiogenic Shock: A Rare Disease Presentation of Diffuse Large B-Cell Lymphoma with Cardiac Involvement
2021
Overview
Extranodal involvement of non-Hodgkin lymphoma (NHL) has been reported in 20–40% of patients and has been typically observed in the skin, bones, gastrointestinal tract, liver and brain. Cardiac involvement has been reported in up to 20% of autopsy cases of patients with NHL and accounts for about 2% of all cardiac malignancies. Here, we report a peculiar case of a secondary cardiac diffuse large B-cell lymphoma (DLBCL), occurring with an abrupt hemodynamic instability, characterized by a sudden ventricular tachycardia and cardiogenic shock. The patient promptly started the first cycle of chemotherapy and was admitted to the cardiac intensive care unit (CICU) of our institution to prevent potential cardiovascular complications during treatment. We applied a fractionated treatment approach, progressively reaching standard doses, to decrease the risk of early death and ensure a successful management.
Publisher
MDPI AG
